Vanguard Group’s Viking Therapeutics VKTX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q4 | $351M | Sell |
9,984,487
-14,620
| -0.1% | -$518K | 0.01% | 1253 |
|
|
2025
Q3 | $263M | Sell |
9,999,107
-163,525
| -2% | -$4.88M | ﹤0.01% | 1402 |
|
|
2025
Q2 | $269M | Sell |
10,162,632
-1,625
| -0% | -$42.8K | ﹤0.01% | 1357 |
|
|
2025
Q1 | $245M | Sell |
10,164,257
-8,184
| -0.1% | -$259K | ﹤0.01% | 1385 |
|
|
2024
Q4 | $409M | Buy |
10,172,441
+4,827
| +0% | +$275K | 0.01% | 1160 |
|
|
2024
Q3 | $644M | Buy |
10,167,614
+70,277
| +0.7% | +$4.12M | 0.01% | 888 |
|
|
2024
Q2 | $535M | Buy |
10,097,337
+2,311,613
| +30% | +$152M | 0.01% | 952 |
|
|
2024
Q1 | $638M | Buy |
7,785,724
+2,403,820
| +45% | +$107M | 0.01% | 870 |
|
|
2023
Q4 | $100M | Buy |
5,381,904
+97,552
| +2% | +$1.28M | ﹤0.01% | 1862 |
|
|
2023
Q3 | $58.5M | Buy |
5,284,352
+171,995
| +3% | +$2.46M | ﹤0.01% | 2055 |
|
|
2023
Q2 | $82.9M | Buy |
5,112,357
+1,053,718
| +26% | +$22.1M | ﹤0.01% | 1948 |
|
|
2023
Q1 | $67.6M | Buy |
4,058,639
+732,968
| +22% | +$7.57M | ﹤0.01% | 2029 |
|
|
2022
Q4 | $31.3M | Sell |
3,325,671
-5,418
| -0.2% | -$24.2K | ﹤0.01% | 2405 |
|
|
2022
Q3 | $9.06M | Hold |
3,331,089
| – | – | ﹤0.01% | 2995 |
|
|
2022
Q2 | $9.63M | Sell |
3,331,089
-349,431
| -9% | -$865K | ﹤0.01% | 3007 |
|
|
2022
Q1 | $11M | Buy |
3,680,520
+296,353
| +9% | +$1.06M | ﹤0.01% | 3098 |
|
|
2021
Q4 | $15.6M | Buy |
3,384,167
+19,215
| +0.6% | +$108K | ﹤0.01% | 2971 |
|
|
2021
Q3 | $21.1M | Buy |
3,364,952
+84,142
| +3% | +$520K | ﹤0.01% | 2836 |
|
|
2021
Q2 | $19.7M | Buy |
3,280,810
+34,619
| +1% | +$206K | ﹤0.01% | 2856 |
|
|
2021
Q1 | $20.5M | Sell |
3,246,191
-138,325
| -4% | -$973K | ﹤0.01% | 2773 |
|
|
2020
Q4 | $19.1M | Buy |
3,384,516
+73,283
| +2% | +$444K | ﹤0.01% | 2657 |
|
|
2020
Q3 | $19.3M | Sell |
3,311,233
-82,910
| -2% | -$571K | ﹤0.01% | 2474 |
|
|
2020
Q2 | $24.5M | Buy |
3,394,143
+30,003
| +0.9% | +$199K | ﹤0.01% | 2324 |
|
|
2020
Q1 | $15.7M | Buy |
3,364,140
+171,670
| +5% | +$1.06M | ﹤0.01% | 2399 |
|
|
2019
Q4 | $25.6M | Buy |
3,192,470
+53,498
| +2% | +$390K | ﹤0.01% | 2409 |
|
|
2019
Q3 | $21.6M | Sell |
3,138,972
-560,863
| -15% | -$4.17M | ﹤0.01% | 2458 |
|
|
2019
Q2 | $30.7M | Buy |
3,699,835
+590,194
| +19% | +$5.04M | ﹤0.01% | 2330 |
|
|
2019
Q1 | $30.9M | Buy |
3,109,641
+520,341
| +20% | +$4.36M | ﹤0.01% | 2308 |
|
|
2018
Q4 | $19.8M | Sell |
2,589,300
-287,987
| -10% | -$3.44M | ﹤0.01% | 2442 |
|
|
2018
Q3 | $50.1M | Buy |
2,877,287
+508,097
| +21% | +$6.05M | ﹤0.01% | 2141 |
|
|
2018
Q2 | $22.5M | Buy |
2,369,190
+855,483
| +57% | +$5.69M | ﹤0.01% | 2519 |
|
|
2018
Q1 | $6.61M | Buy |
1,513,707
+527,955
| +54% | +$2.92M | ﹤0.01% | 3030 |
|
|
2017
Q4 | $4M | Buy |
985,752
+646,963
| +191% | +$1.88M | ﹤0.01% | 3210 |
|
|
2017
Q3 | $647K | Buy |
338,789
+8,100
| +2% | +$9.2K | ﹤0.01% | 3691 |
|
|
2017
Q2 | $357K | Hold |
330,689
| – | – | ﹤0.01% | 3788 |
|
|
2017
Q1 | $483K | Buy |
330,689
+60,467
| +22% | +$84.5K | ﹤0.01% | 3759 |
|
|
2016
Q4 | $322K | Buy |
270,222
+49,926
| +23% | +$56.3K | ﹤0.01% | 3814 |
|
|
2016
Q3 | $313K | Buy |
220,296
+14,721
| +7% | +$19.5K | ﹤0.01% | 3834 |
|
|
2016
Q2 | $259K | Buy |
205,575
+185,300
| +914% | +$244K | ﹤0.01% | 3901 |
|
|
2016
Q1 | $29K | Buy |
20,275
+1,400
| +7% | +$2.81K | ﹤0.01% | 4109 |
|
|
2015
Q4 | $64K | Buy |
18,875
+600
| +3% | +$2.69K | ﹤0.01% | 4118 |
|
|
2015
Q3 | $106K | Hold |
18,275
| – | – | ﹤0.01% | 4088 |
|
|
2015
Q2 | $130K | Buy |
+18,275
| New | +$151K | ﹤0.01% | 4095 |
|
Other funds holding VKTX
Vanguard Group's VKTX Position: Q4 2025 in Review
Vanguard Group reduced its Viking Therapeutics (VKTX) stake by 0.15% in Q4 2025, selling an estimated $518K and leaving 9,984,487 shares worth $351M. The position accounts for 0.01% of the portfolio, ranked #1253.
Vanguard Group first reported a position in VKTX in Q2 2015 and has held it in 43 quarters since. The position peaked at $644M in Q3 2024. 424 funds tracked by Wall St. Rank hold VKTX as of Q4 2025.
- Vanguard Group held 9,984,487 shares of Viking Therapeutics worth $351M as of Q4 2025.
- Vanguard Group sold 14,620 Viking Therapeutics shares in Q4 2025, an estimated $518K.
- Viking Therapeutics made up 0.01% of Vanguard Group's portfolio in Q4 2025, its #1253 holding.
- Vanguard Group first reported a position in Viking Therapeutics in Q2 2015 and has held it in 43 quarters since.
- Vanguard Group's Viking Therapeutics position peaked at $644M in Q3 2024.
- 424 funds tracked by Wall St. Rank held Viking Therapeutics as of Q4 2025.
Based on Vanguard Group's 13F filing for Q4 2025, filed 29 Jan 2026.